Search Results - rsv+virus

3 Results Sort By:
Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response
This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...
Published: 10/28/2024   |   Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp
Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics
CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus
CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are...
Published: 4/8/2024   |   Inventor(s): Larry Anderson, Michael Brown, Ralph Tripp
Keywords(s): adjuvant, CD40, CD40L, CDC Docket Import, CDC Docket Import CDC Prosecuting, Costimulation, COSTIMULATORY, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, LIGAND, OID-NCIRD-DVD, respiratory, RSV, RSV virus, Synctial, Vacccination, Vaccine, virus, VLXXXX, WJXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines
Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation
Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral...
Published: 10/28/2024   |   Inventor(s): Peter Collins, Brian Murphy, Ursula Buchholz, Stephen Whitehead, Christine Krempl
Keywords(s): ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines